OPK

OPKO Health, Inc. - 10-Q Summary (Q1 2009)

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2009. OPKO Health, Inc. is a specialty healthcare company focused on the discovery, development, and commercialization of proprietary pharmaceuticals, diagnostic, and imaging systems for ophthalmic diseases. The company operates in two primary areas: ophthalmic pharmaceuticals (currently in development) and ophthalmic instrumentation (commercialized).

Key Financial Metrics

Note: Debt includes a fully utilized $12.0 million line of credit with a related party and current notes payable.

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased by approximately 18% year-over-year, primarily due to reduced orders from international distributors for the OCT/SLO product following lower participation in trade shows in early 2009. This was partially offset by new U.S. sales.
• Gross Margin Improvement: The company moved from a gross deficit of $0.5 million in Q1 2008 to a gross margin of $0.7 million in Q1 2009. This improvement resulted from cost reduction initiatives and supplier changes implemented in 2008.
• SG&A Reduction: Selling, general, and administrative expenses dropped significantly from $5.3 million to $3.3 million. This decrease was driven by lower personnel costs and the absence of $1.4 million in stock option acceleration expenses recorded in Q1 2008.
• R&D Increase: Research and development expenses rose from $4.4 million to $5.7 million. The increase reflects costs associated with the Phase III clinical trial for bevasiranib, including shutdown costs incurred after the trial was terminated on March 6, 2009.
• Liquidity Position: Cash and cash equivalents declined from $6.7 million at the end of 2008 to $2.2 million at March 31, 2009, due to operating cash burn.

Outlook, Risks, and Unusual Items

• Capital Raise (Subsequent Event): On April 27, 2009, the company closed a $20.0 million private placement with the Frost Gamma Investments Trust (controlled by Chairman/CEO Phillip Frost), issuing 20 million shares at $1.00 per share. Proceeds were used to repay a $3.0 million bridge loan.
• Clinical Trial Termination: The Phase III clinical trial for bevasiranib was terminated following a recommendation by the Independent Data Monitoring Committee. The company anticipates ceasing all activities related to this trial by the third quarter of 2009.
• Liquidity Outlook: Management believes cash on hand combined with the $20 million investment received in April 2009 will be sufficient to fund operations for the next 12 months. However, the company expects to incur substantial losses in the foreseeable future and may require additional funding.
• Risk Factors: Key risks include the history of operating losses, the unproven nature of technologies, reliance on third-party manufacturers, and the need for substantial additional funding. The company has no experience manufacturing pharmaceutical products and relies on third parties.
• Legal Proceedings: A lawsuit filed by Ophthalmic Imaging Systems (OIS) was settled in April 2009. The company stated the net impact was not material.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $20 million capital raise to cover the projected burn rate given the termination of the bevasiranib trial and continued R&D needs.
• Related Party Transactions: Review the terms of the $12 million line of credit and the $20 million equity investment, both involving entities controlled by the Chairman/CEO.
• Revenue Concentration: Assess the risk associated with international distributors, which accounted for significant portions of revenue (top three customers represented ~55% of revenue in Q1 2009).
• Product Pipeline: Confirm the status of remaining product candidates following the termination of the bevasiranib Phase III trial.
• Debt Obligations: Monitor the maturity and interest terms of the related-party line of credit due in January 2011.